Literature DB >> 25957639

Walking function in clinical monitoring of multiple sclerosis by telemedicine.

Núria Sola-Valls1, Yolanda Blanco, Maria Sepúlveda, Sara Llufriu, Elena H Martínez-Lapiscina, Delon La Puma, Francesc Graus, Pablo Villoslada, Albert Saiz.   

Abstract

Walking limitation is a key component of disability in patients with multiple sclerosis (MS), but the information on daily walking activity and disability over time is limited. To determine, (1) the agreement between the standard measurements of MS-related disability [expanded disability status scale (EDSS), functional systems (FS) and ambulation index (AI)] obtained by conventional and remote evaluation using a multimedia platform; (2) the usefulness of monitoring 6-min walk test (6MWT) and average daily walking activity (aDWA) to better characterize patients disability. Twenty-five patients (EDSS score 1.0-6.5) were evaluated every 3 months for the first year, and aDWA repeated at year 2. Remote visits included the recording of a video with self-performed neurological examination and specific multimedia questionnaires. aDWA was measured by a triaxial accelerometer. All but two patients completed the study. Modest agreement between conventional and multimedia EDSS was found for EDSS ≤ 4.0 (kappa = 0.2) and good for EDSS ≥ 4.5 (kappa = 0.6). For the overall sample, pyramidal, cerebellar and brainstem FS showed the greatest agreement (kappa = 0.7). SR-AI showed a modest agreement for EDSS ≤ 4.0 and good for EDSS ≥ 4.5 (kappa = 0.3 and 0.6, respectively). There was a strong correlation between conventional and 6MWT measured by accelerometer (r = 0.76). The aDWA correlated strongly with the EDSS (r = -0.86) and a cut-off point of 3279.3 steps/day discriminated patients with ambulatory impairment. There was a significant decline in aDWA over 2 years in patients with ambulatory impairment that were not observed by standard measurements of disability. MS clinical monitoring by telemedicine is feasible, but the observed lower agreement in less disabled patients emphasizes the need to optimize the assessment methodology. Accelerometers capture changes that may indicate deterioration over time.

Entities:  

Mesh:

Year:  2015        PMID: 25957639     DOI: 10.1007/s00415-015-7764-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences.

Authors:  M H Verdier-Taillefer; M Zuber; O Lyon-Caen; M Clanet; O Gout; C Louis; A Alpérovitch
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

2.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

3.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

Authors:  M P Amato; L Fratiglioni; C Groppi; G Siracusa; L Amaducci
Journal:  Arch Neurol       Date:  1988-07

4.  Steps per day among persons with multiple sclerosis: variation by demographic, clinical, and device characteristics.

Authors:  Deirdre Dlugonski; Lara A Pilutti; Brian M Sandroff; Yoojin Suh; Swathi Balantrapu; Robert W Motl
Journal:  Arch Phys Med Rehabil       Date:  2013-02-15       Impact factor: 3.966

5.  Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures.

Authors:  Domien Gijbels; Geert Alders; Elke Van Hoof; Caroline Charlier; Machteld Roelants; Tom Broekmans; Bert Op 't Eijnde; Peter Feys
Journal:  Mult Scler       Date:  2010-03-05       Impact factor: 6.312

6.  Reliability of distance estimation by doctors and patients: cross sectional study.

Authors:  B Sharrack; R A Hughes
Journal:  BMJ       Date:  1997 Dec 20-27

Review 7.  The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Authors:  Chris H Polman; Richard A Rudick
Journal:  Neurology       Date:  2010-04-27       Impact factor: 9.910

8.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

9.  Clinical importance of steps taken per day among persons with multiple sclerosis.

Authors:  Robert W Motl; Lara A Pilutti; Yvonne C Learmonth; Myla D Goldman; Ted Brown
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  Home-based system for physical activity monitoring in patients with multiple sclerosis (Pilot study).

Authors:  Layal Shammas; Tom Zentek; Birte von Haaren; Stefan Schlesinger; Stefan Hey; Asarnusch Rashid
Journal:  Biomed Eng Online       Date:  2014-02-06       Impact factor: 2.819

View more
  7 in total

1.  Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial.

Authors:  Patrick Altmann; Fritz Leutmezer; Markus Ponleitner; Dominik Ivkic; Nik Krajnc; Paulus Stefan Rommer; Thomas Berger; Gabriel Bsteh
Journal:  Digit Health       Date:  2022-07-11

2.  A comparison of telemedicine and in-person neurology visits: what are the factors that patients consider when selecting future visit type?

Authors:  Carly Olszewski; Sharon Thomson; Kelly Pring; Siobhan Cox; Rebecca Merrill; Emily Fishman; Alexander Ambrosini; Kevin Alexander Soltany; Gabby Bognet; Lauren Strauss; Rachel Graham; Amy Guzik; Roy E Strowd
Journal:  J Neurol       Date:  2022-05-05       Impact factor: 6.682

3.  Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine.

Authors:  Núria Sola-Valls; Yolanda Blanco; María Sepúlveda; Sara Llufriu; Elena H Martínez-Lapiscina; Irati Zubizarreta; Irene Pulido-Valdeolivas; Carmen Montejo; Pablo Villoslada; Albert Saiz
Journal:  Ther Adv Neurol Disord       Date:  2018-06-10       Impact factor: 6.570

4.  Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service Perspective.

Authors:  Francesco Corea; Silvia Ciotti; Antonella Cometa; Claudia De Carlo; Giancarlo Martini; Silvano Baratta; Mauro Zampolini
Journal:  Neurol Int       Date:  2021-01-18

Review 5.  Mobile health (mHealth) usage, barriers, and technological considerations in persons with multiple sclerosis: a literature review.

Authors:  Elizabeth S Gromisch; Aaron P Turner; Jodie K Haselkorn; Albert C Lo; Thomas Agresta
Journal:  JAMIA Open       Date:  2020-12-15

6.  Face-to-Face or Telematic Cognitive Stimulation in Patients with Multiple Sclerosis and Cognitive Impairment: Why Not Both?

Authors:  C Guijarro-Castro; Y Aladro-Benito; A Sánchez-Musulim; A Belen-Caminero; I Pérez Molina; I Gómez-Moreno; L Gómez-Romero; J Millán-Pascual; M J Laredo; M Cerezo-García
Journal:  Behav Neurol       Date:  2017-12-13       Impact factor: 3.342

7.  The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review.

Authors:  Martin Marziniak; Giampaolo Brichetto; Peter Feys; Uta Meyding-Lamadé; Karen Vernon; Sven G Meuth
Journal:  JMIR Rehabil Assist Technol       Date:  2018-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.